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INTRODUCTION
Alloreactive T cells are involved in graft-vs.-host disease
(GVHD) in allogeneic bone marrow transplantation, and
depletion of T cells from the marrow has been successful in
reducing the incidence and severity of both acute and
chronic GVHD [1–4]. The benefits of T cell depletion,
however, are largely offset by an increase in the risk of
leukemia relapse, most pronounced in human leukocyte
antigen (HLA)-identical sibling transplants for standard-risk
leukemia [3,5–7]. The risk of graft failure is also increased
up to 20%, with variable results among different studies,
depending on the degree of depletion, the degree of HLA
match, and the conditioning regimens [4,8–10].
Previous clinical studies indicate the importance of clin-
ically evident GVHD for the graft-vs.-leukemia (GVL)
effect, corroborating experimental data that reveal the pres-
ence of immunocompetent donor cells recognizing allo-
specific molecules expressed on both normal and leukemic
cells [5,11–14]. These clinical observations support the con-
cept that leukemia-specific, as well as overlapping subsets of
donor-derived T cells, mediate both the GVL effect and
GVHD. Experimental studies and clinical observations have
well documented the presence of anti-leukemic activity
from immunocompetent donor T cells independent of abla-
tive therapy and have shown that the responses of posttrans-
plant relapse of leukemia to the infusion of donor lympho-
cytes are largely correlated with both acute and chronic
GVHD [15–19]. Although several investigators have sug-
gested that cytokines or natural killer cells may also play a
role, the majority of experimental data indicate T cells are
the primary mediators of the GVL effect through recogni-
tion of leukemia-specific molecules on the cell surface
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ABSTRACT
To increase the graft-vs.-leukemia (GVL) effect while maintaining a low mortality from graft-vs.-host disease
(GVHD), we conducted a prospective study of T cell titration for 144 patients (90 related, 54 unrelated) between
June 1994 and June 1997. Following infusion of a T cell–depleted marrow graft, predetermined doses of T cells,
based on the risk factors for GVHD, were administered up to 3 times if greater than a grade II acute GVHD was not
seen. Graft failure occurred in three unrelated recipients (2%). Cumulative grades II–IV acute GVHD were seen in
58 6 9% of all recipients; 52 6 11% related and 75 6 13% unrelated. The incidence of grades II–IV acute GVHD
following the third add-back (AB) of T cells 78 median days after marrow infusion was lower than that of the earlier
ABs: first AB, 36 6 8%; second AB, 32 6 11%; third AB, 15 6 12% (p , 0.05). Chronic GVHD occurred in 56 6
12% of related and 79 6 16% of unrelated patients. Six died of acute GVHD and two died of chronic GVHD, with
an overall GVHD mortality of 6 6 4%. In multivariate analyses, unrelated recipients and patients at low risk for
GVHD who received a larger number of T cells were identified as patient groups with significant risk for acute and
chronic GVHD (both p , 0.05). Unrelated transplant is also shown to be significant for GVHD-related death 
(p , 0.01). Relapse-free survival of patients with leukemia was shown to be most dependent on chronic GVHD and
grades II–IV acute GVHD (both p , 0.01). Anti-leukemic activity independent of GVHD was not observed.
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[20–25]. A GVL effect distinguishable from GVHD appears
to be dependent on the antigen specificity and functional
activity of the responding T cells, yet it remains to be clari-
fied which subset of or interaction between cells leads to the
anti-leukemic effect without overlapping GVHD [26–29].
In that regard, the study of Mackinnon et al. indicated that
there was a threshold number of donor T cells required to
evoke anti-leukemic effect and GVHD [30]. This suggests
there is a quantitative component of the interaction.
Control of GVHD by T cell depletion has been shown
to be affected by several factors, including the number of T
cells in the graft [31–32], the additional infusion of T cells
[33–34], and the posttransplant immunosuppressive therapy
[4]. These studies indicate the threshold for the development
of GVHD is in the range of 0.5–13105 T cells/kg, and rein-
fusion of 1–2.53105 additional T cells/kg is associated with a
low frequency of both acute and chronic GVHD. In our pre-
vious T cell add-back (AB) study, based on the GVHD risk
factors for patients with T cell–depleted bone marrow trans-
plant (BMT), 13105 T cells/kg were administered to
patients who received HLA-mismatched or unrelated grafts
or who were older than 35 years, whereas 2.53105 T cells/kg
were given to those with HLA-matched related grafts who
were younger than 36 years [35–38]. In this study, the inci-
dence of grades II–IV acute GVHD and extensive chronic
GVHD was 30 and 15%, respectively, and chronic GVHD
was associated with an increase in leukemia-free survival. In
1994, we initiated the current study to improve on the GVL
effect we had observed in previous results through delayed
sequential infusion of more T cells, based on reports that
delayed infusion enhances GVL without GVHD [22,39–40].
The total number of T cells infused was based on previous
studies of T cell–depleted BMT [32,38,41–43] and divided
into three separate incremental doses to see whether there
was a dose-response relationship between GVHD and the
T cell dose in the range of 1–103105 T cells/kg. The
GVHD risk group was defined by HLA status, related vs.
unrelated grafts, and age. The 4- to 6-week intervals
between each T cell AB were based on our experience of
donor leukocyte infusions in agreement with the median
time to development of acute GVHD in a published series
[19]. The first pilot cohort of 37 patients validated the design
of the study [44] and the subsequent preliminary analysis
suggested separate GVL effects from chronic GVHD [45].
We now report on the statistically pertinent data of 144
patients treated through June 1997.
METHODS
Patients
One hundred forty-four patients with hematologic
malignancies who received allogeneic BMT at the Univer-
sity of Iowa Hospitals and Clinics were accrued consecu-
tively between June 1994 and June 1997. The Institutional
Review Board of the University of Iowa College of Medi-
cine, University of Iowa, approved all treatment protocols
and written informed consent was obtained from all patients
or their guardians. Patient and donor characteristics are
shown in Table 1.
The study includes 53 patients with standard-risk
leukemia and 45 patients with high-risk leukemia. High-
risk leukemia was defined as acute myelogenous leukemia
(AML; n55) and acute lymphocytic leukemia (ALL; n52)
in chemoresistant relapse or greater than second remission,
AML (n53) in second remission after ,1 year of first
remission, AML from myelodysplastic syndrome (MDS;
n56), AML (n59 ) or ALL (n55) with unfavorable cytoge-
netics in first remission, chronic myelogenous leukemia
(CML) in accelerated or blastic phase (n59), relapsed
CML after BMT (n53), and MDS with excess blasts or
blasts in transformation (n53). Other leukemias were clas-
sified as standard-risk.
Histocompatibility testing and donor selection
The tissue typing laboratory of the University of Iowa
confirmed HLA typing for all patients and donors. A stan-
dard two-stage microcytotoxicity assay was used to test class
I HLA antigens. Class II HLA antigens were assessed by
either microcytotoxicity assay (n524) or allele typing of
DRB1 with sequence-specific oligonucleotide hybridization
(n5120). In the first 36 patients, a microcytotoxicity cross-
match assay with lymphoblastoid cell lines was done concur-
rently. Unrelated donor marrow was procured through the
National Marrow Donor Program, the Anthony Nolan
Bone Marrow Trust, the German National Registry of Bone
Marrow Donors, the Irish Unrelated Bone Marrow Panel,
and donor centers in Finland, Norway, and Sweden. When
identical at HLA-A, B, and D/DRB1 loci, donor and patient
pairs were considered matched. Except for two sibling pairs
with a B major antigen mismatch, HLA class I mismatches
were defined by a single split or single disparity in the same
cross-reactive group. HLA class II mismatches were allowed
if defined by a single high-resolution DNA-DRB1 disparity
or a serological DR mismatch as defined by a single split or
Table 1. Demographic data
Characteristics Number of patients
Median age 44 years (range 18–60)
Sex Male/female 89/55
Donors Related/unrelated 90/54
HLA Matched/mismatched 124/20
Disease AML 32
MDS 14
CML 35
ALL 10
CLL 7
NHL 26
MM 16
Miscellaneous 4
GVHD riska Low 18 (18)
Intermediate 78 (75)
High 48 (34)
aGVHD risk: see Table 2. Number in parentheses represents patients who
received at least one add-back of T cells.
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia;
CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia;
HLA, human leukocyte antigen; MDS, myelodysplastic syndrome; NHL, 
non-Hodgkin’s lymphoma; MM, multiple myeloma; Miscellaneous, 2 chronic
myeloproliferative disorders, 2 idiopathic eosinophilia syndromes.
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single disparity in the cross-reactive group with a nonreac-
tive mixed lymphocyte culture.
Patients with an HLA-identical sibling or HLA pheno-
typically matched, related donor were eligible through 60
years of age. Patients with an unrelated donor, a mismatched
donor at one antigen, or a donor with phenotypically
matched HLA antigens in GVHD direction (homozygous
recipient) were eligible through 55 years of age.
Transplantation procedure
Fifty-four patients received a regimen of Ara-C at 
18 g/m2 in six divided doses every 12 hours (Days –8, –7, –4,
–3), cyclophosphamide at 60 mg · kg21 · day21 for 2 days
(Days –6, –5), and total-body irradiation (TBI) of 1200 cGy
in six fractions with lungs shielded to a dose of 800 cGy (Days
–2 through 0). Twenty-seven patients were given a similar
regimen except the second dose of cyclophosphamide, which
was replaced by thiotepa at 240 mg/m2 (Day –5) to reduce
cyclophosphamide cardiotoxicity. Forty-eight patients with
lymphoid malignancies except ALL received the same TBI
(Days –8, –7, –6) followed by BCNU at 300 mg/m2 (Day –5),
etoposide at 600 mg · m22 · day21 for 2 days (Days –3, –2),
Ara-C at 2 g/m2 every 12 hours for 4 doses (Days –4, –3, –2),
and cyclophosphamide at 90 mg/kg (Day –2). Ten patients
with ALL received 1350 cGy of TBI in nine fractions with
lungs shielded to a dose of 800 cGy (Days –8 through –4) and
400 cGy testicular boost for male patients and etoposide at 
60 mg/kg (Day –3). Four patients were treated with busulfan
at 4 mg · kg21 · day21 for 4 days (Days –7 through –4) and
cyclophosphamide at 60 mg · kg21 · day21 for 2 days (Days –3,
–2). One patient was given BCNU at 450 mg/m2 (Day –9),
etoposide at 400 mg · m22 · day21 for 4 days (Days –7 through
–4), Ara-C at 24 g/m2 in eight divided doses every 12 hours
(Days –8 through –4) and cyclophosphamide at 60 mg · kg21 ·
day21 for 2 days (Days –3, –2).
All patients were housed in private rooms with a laminar
airflow system equipped with high efficiency particulate air
filters. For antimicrobial prophylaxis, trimethoprim-
sulfamethoxazole at one double strength tablet twice a day
and daily intravenous amphotericin B at 20 mg were given
during the ablative therapy. During neutropenia of absolute
neutrophil count (ANC) below 500/mL, same dose ampho-
tericin B and antibiotics covering gram-negative organisms
were administered until engraftment. Febrile episodes during
neutropenia were treated with combination therapy of a
broad-spectrum cell wall–acting agent (synthetic penicillins
or cephalosporines) and an aminoglycoside. Acyclovir at
between 250 mg · m22 · day21 and 250 mg/m2 every 8 hours
was started on Day 1, trimethoprim-sulfamethoxazole at the
same dose was restarted after engraftment, and both were
continued for 6 months. Ganciclovir was administered to
cytomegalovirus (CMV)-positive patients during the ablative
therapy at 10 mg · kg21 · day21 and after engraftment in a
tapering scheme of 5 mg · kg21 · day21 for 7 days, then 10 mg ·
kg21 · week21 until week 10, then 10 mg/kg every 3 weeks for
a total of 6 months. The same posttransplant ganciclovir pro-
phylaxis was given to CMV-negative patients whose donor
was CMV-positive. Granulocyte colony-stimulating factor
(G-CSF) was administered at 300 mg beginning on Day 1
(n538) or on Day 7 (n5102) and continued until engraft-
ment. Prophylactic intravenous immunoglobulin (Ig) admin-
istered through 6 months posttransplant. During hospitaliza-
tion for transplantation, both hemoglobin and platelets were
maintained at .10 g/dL and .20,000/mL, respectively.
GVHD prophylaxis was done by ex vivo depletion of
marrow T cells, and intravenous methylprednisolone at 
1 g/m2 and cyclosporine at 4 mg/kg on Days –1 and 0.
Thereafter, a trough level of whole blood cyclosporine was
maintained between 150 and 350 ng/mL by a monoclonal
antibody assay for patients who developed grades II–IV acute
GVHD or chronic GVHD. Patients who did not develop
GVHD or whose GVHD became well controlled received a
tapering dose of cyclosporine at a rate of 0.3–0.5 mg/kg
every 2 weeks. Steroids were added for initial therapy of both
acute GVHD of grade greater than II and chronic GVHD.
For the first 22 patients, T cells were depleted by an anti-
CD2 IgM mouse monoclonal antibody (CT-2) to the 
E-rosette receptor on T lymphocytes and newborn rabbit
serum as a source of complement [46]. After depletion,
87.9% mononuclear cells were recovered at a mean of 1.93 6
0.16 (SD)3108/kg. Flow cytometric measurements revealed
the marrow CD31 (T3) T cells were reduced by a median of
2.06 log to 2.3 6 0.383105/kg, the Leu4 CD31 T cells by a
2.03 log to 2.54 6 0.413105/kg, the CD21 (T11) T cells by a
2.3 log to 1.48 6 0.63105/kg, and the CD41CD81 T cells by
a 1.7 log to 5.32 6 0.623105/kg. For the remaining 122
patients, T cells were depleted by an anti-CD3 IgG2 mono-
clonal antibody (muromonab-CD3, Ortho Biotec, Raritan,
NJ) [47]. Briefly, the muromonab-CD3 was added to marrow
at a concentration of 0.625 m g/mL for a 30-minute incuba-
tion at room temperature with agitation. Newborn rabbit
serum was then added at a volume ratio of 0.85 to the volume
of marrow and muromonab-CD3 mixture for a 90-minute
incubation at room temperature with agitation. The excess
serum was removed afterwards and the treated marrow cells
were resuspended in 100 mL of fresh frozen plasma with
heparin at 20 U/mL. The mononuclear cells were recovered
at a mean of 2.25 6 1.11 3108/kg. The marrow CD31 (T3)
cells were reduced by a median of 2.28 log to 0.77 6 0.36
3105/kg, the Leu4 CD31 T cells by a 2.18 log to 1.05 6 0.42
3105/kg, the CD21 (T11) T cells by a 1.85 log to 1.67 6
0.32 3105/kg, and the CD41CD81 T cells by a 2.0 log to
1.13105/kg. A comparative analysis of T cell–depletion did
not reveal differences between these two methods [48].
For T cell titration, patients were divided into three risk
groups for GVHD based on the HLA status, source of mar-
row, and age (Table 2). Fresh peripheral blood T cells were
used for the first AB and cryopreserved marrow T cells were
given for subsequent ABs. CD31 T cells in the mononuclear
Table 2. GVHD risk groups
Risk group HLA status, source of marrow, and age
Low Matched siblings and #35 years
Intermediate Matched siblings and 36–50 years
Matched unrelated and #50 years
High Matched siblings and 51–60 years
Matched unrelated and 51–55 years
Phenotypically matched related and #60 years
Any mismatched recipients
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fraction of either peripheral blood or harvested marrow
were flow-cytometrically measured. An aliquot of peripheral
blood containing a predetermined number of CD31 T cells
was resuspended in 60 mL of fresh frozen plasma for imme-
diate infusion and two aliquots of harvested marrow were
resuspended in 60 mL of RPMI-1680 (Gibco, Grand Island,
NY) and 6 mL of DMSO (Research Industry, Midvale, UT)
for cryopreservation. Each bag of marrow T cells was frozen
first by a rate-controlled freezer over an hour, followed by
cryopreservation in a liquid nitrogen freezer to –150 ° C or
less. Patients were eligible for incremental ABs as long as
the grade of acute GVHD was less than II without therapy
except prophylactic cyclosporine at the time of planned AB
(Table 3). The time of ABs was arranged to let patients
recover from acute transplant toxicity and to be adequately
monitored for GVHD before and after T cell infusion.
Statistical analysis
Patients were studied prospectively for GVHD, engraft-
ment, relapse, and death. Where applicable, descriptive data
were presented with a mean 6 95% confidence interval. The
onset and duration of the event were presented with median
values. The day of myeloid engraftment was defined as the
first of 3 consecutive days with an ANC . 500/mL. Primary
graft failure was defined as the absence of engraftment in
patients surviving for at least 28 days after transplantation.
Secondary graft failure was defined as myeloid engraftment
followed by a persistent decrease in an ANC to below
100/mL. To be evaluable for engraftment, patients had to sur-
vive at least 28 days. Acute and chronic GVHD were graded
according to published criteria [37,49–50]. Independent vari-
ables for analyses were diagnosis, related vs. unrelated donor,
HLA status, risk groups for GVHD, and total number of T
cell AB –administered; dependent variables were grade and
duration of acute GVHD after each AB, overall acute
GVHD, grade and duration of chronic GVHD, relapse-free
survival, and event-free survival. Two-way analysis of variance
was used for comparison of the duration of GVHD. Pearson’s
chi square analysis was used for comparison of the incidence
of acute GVHD after each AB of T cells. The cumulative risk
analyses of GVHD and survival analyses were done by the
product limit estimate of the Kaplan-Meier method. For mul-
tivariate analyses, variables with a p , 0.1 in univariate analy-
sis were put into a stepwise multivariate regression by the
Cox proportional hazard model.
RESULTS
Engraftment
Median time to engraftment was 14 days, with a range
from 11 to 27 days. Two patients had primary graft failure
and one had secondary failure, for an overall incidence of
2%. All three patients were unrelated-donor recipients.
T cell ABs and grades II–IV acute GVHD are shown in
Table 4.
First AB
Of 137 eligible patients for the first AB, 127 received T
cells. Four high-risk patients did not receive T cells because
of acute GVHD and six patients died of non–GVHD-
related complications before T cell AB. The median onset
and duration of grades II–IV were 24 (range 1–60 days) and
70 days (range 5–100 days) after AB, respectively. Forty-six
patients (36 6 8%) had grades II–IV, with 22 6 7% grade
II. Unrelated recipients had a higher risk of grades II–IV
than related recipients, p , 0.05 (Fig. 1). There was no dif-
ference among the three risk groups, and between HLA-
matched and -mismatched pairs, with p 5 0.32 and 0.72,
respectively.
In HLA-matched sibling transplants, there was no differ-
ence in the risk of acute GVHD after the first AB between
those who were ,36 years and received 2.53105 T cells/kg
concurrently with marrow infusion and those who were .50
years and received 13105 T cells/kg after engraftment in a
median of 19 days posttransplant with a range of 10–43 days
(37 6 13 vs. 43 6 23%, respectively; p 5 0.86.
Second AB
Seventy-one of 81 patients in the three risk groups
received the second AB. Of the remaining 10 patients, nine
died before the AB and one patient was excluded by an
attending physician due to an unrelated complication. The
median onset and duration of grades II–IV were 17 (range
4–40 days) and 70 days (range 14–100 days) after AB,
respectively. The most common GVHD was grade II in 20
Table 3. Scheme of T cell titration
Risk
Add-back Low Intermediate High
First Day 0 Day 0 ANCa . 500 3 3 days
2.53105/kg 13105/kg 13105/kg
Second 4th–6th week 4th–6th week 6th–8th week
53105/kg 2.53105/kg 2.53105/kg
Third 10th–12th week 10th–12th week 12th–14th week
13106/kg 7.53105/kg 7.53105/kg
aANC, absolute neutrophil count/mL.
First row of each add-back, time of add-back in relation to transplantation;
second row of each add-back, number of T cells.
Table 4. GVHD after T cell add-back
Time of add-backa
Add-back (Day) Receivedb GVHD II–IVc
Low-risk
First 01 18 8
Second 39111 8 3
Third 49111 5 1
Intermediate-risk
First 0 75 29
Second 38111 42 9
Third 30111 20 2
High-risk
First 2111 34 9
Second 33111 21 11
Third 30111 9 2
aDay 01, the day of transplantation; Day 2111, median day in relation to
transplantation; Days111, median days in relation to the previous add-back.
bNumber of patients who received T cell add-back.
cNumber of patients who developed grades II–IV GVHD after add-back.
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6 9%. Of 23 patients (32 6 11%) who developed grades
II–IV, unrelated recipients showed a higher risk than related
recipients, p , 0.01 (Fig. 2). The high-risk patients had the
highest risk of GVHD among the three risk groups, p , 0.1
(Fig. 3). There was no difference by HLA status. Multivari-
ate analysis revealed unrelated donor transplant as most
significant for grades II–IV acute GVHD after the second
AB (Table 5).
Third AB
Thirty-four of 48 eligible patients received the third AB.
Of 14 patients who did not receive the third AB, nine died
before the AB and five were excluded because of other com-
plications. Only five related recipients (15 6 12%) devel-
oped grades II–IV GVHD in a median of 21 days (range
9–35 days), which is significantly lower than GVHD after
each first or second AB, p , 0.05. The median duration of
grades II–IV was 100 days (range 80–100 days). There was
no difference among the three risk groups, p 5 0.69.
Overall acute GVHD
The cumulative incidence of grades II–IV acute GVHD
for all eligible patients is 58 6 9%, with grade II as the most
common (34 6 8%). The low-risk group had the highest
risk of grades II–IV among the three groups, p 5 0.08 (Fig.
3). Unrelated recipients had a higher risk than related recipi-
ents, p , 0.05 (Fig. 2). There was no difference based on the
HLA status, p 5 0.67. Both the low-risk group and unre-
lated recipients were shown to be significant in multivariate
analysis (Table 5). Durations of grades II–IV acute GVHD
following each AB and grades II–IV overall acute GVHD
were not shown to be associated with any variables.
Sixty-one patients (77 6 9%) responded to initial ther-
apy with steroids added to cyclosporine, and the remaining
18 patients required secondary therapy. Of these, eight
patients did not respond to the treatment: four after the first
AB, three after the second, and one after the third.
Chronic GVHD
Of 92 at-risk patients, 24 (26 6 9%) developed limited
chronic GVHD and 29 had extensive GVHD (32 6 7%).
Median day of onset and duration were Day 140 (range
100–280 days) and 100 days (range 16–688 days) for limited
GVHD, and Day 145 (range 100–209 days) and 240 days
(range 50–970 days) for the extensive GVHD, respectively.
Chronic GVHD occurred most frequently in the low-risk
group compared with both intermediate- and high-risk
groups, p 5 0.07 (Fig. 3). Unrelated recipients had a higher
risk than related recipients, p , 0.01 (Fig. 2). Patients who
received two ABs had the highest risk of GVHD compared
with patients with one or three ABs, p , 0.01 (Fig. 4).
Forty-four patients with preceding grades II–IV acute
GVHD had a higher risk of chronic GVHD than the other
48 patients who did not show acute GVHD, with p , 0.01
(Fig. 4). Multivariate analysis showed the low-risk group
and unrelated recipients as most significant for chronic
Figure 1. Kaplan-Meier plots of the proportional incidence of
acute GVHD
(—), unrelated BMT; ( ), related BMT.
Figure 2. Kaplan-Meier plots of the proportional incidence of
acute and chronic GVHD
Acute GVHD starts on Day 0 and chronic GVHD on Day 100. (—), unre-
lated BMT; ( ), related BMT. 
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GVHD (Table 5). Duration of chronic GVHD was not
shown to be associated with any variables.
GVHD-related nonrelapse death
Eight of 54 unrelated recipients died of GVHD: two
before the first AB, three after the first AB (median survival
of 39 days post-AB), one 114 days after the second AB, and
two of chronic GVHD. None of the low-risk patients died
of acute GVHD, whereas three patients from each interme-
diate- and high-risk group died. Additionally, four related
and four unrelated recipients died of secondary infectious
complications while on therapy for GVHD. All 16 patients
were included in the analysis of the cumulative risk of death.
Unrelated recipients showed a higher risk of death than
related recipients, p , 0.01 (Fig. 5). HLA-mismatched
patients showed a minimally higher risk of death than HLA-
matched patients, p 5 0.07 (Fig. 5). There was no difference
among the three risk groups. Multivariate analysis showed
unrelated recipients to have a significantly higher risk for
GVHD-related death (Table 5).
Non–GVHD-related nonrelapse death
There were seven deaths in the first 28 days of BMT.
Four patients died of acute restrictive cardiomyopathy due
to cyclophosphamide before Day 8 [51], one of idiopathic
intracerebral hemorrhage on Day 0, one of idiopathic
pneumonia syndrome, and one of invasive aspergillosis, the
latter 2 occurring after engraftment. During the period of
29–200 days posttransplant, 38 patients died of nonrelapse
transplant-related complications. Of these, nine died of
idiopathic pneumonia syndrome, eight of bacterial sepsis,
six of CMV disease, five of invasive fungal infection, three
of veno-occlusive disorder of the liver, one of respiratory
syncytial virus pneumonia, one of toxoplasmosis, and five of
other noninfectious toxicities. Beyond Day 200 posttrans-
plant, four died of bacterial sepsis, two of CMV disease,
two of idiopathic pneumonia syndrome, one of influenza,
one of mucormycosis, and two of unknown causes.
Relapse-free survival
Of patients with both standard- and high-risk leukemia
who developed chronic GVHD, 6.3% showed relapse;
whereas 33 6 22% patients without chronic GVHD relapsed
in 16 months of median follow-up, p , 0.01 (standard-risk
leukemia, 0% with and 33 6 17% without chronic GVHD, 
p 5 0.06; high-risk leukemia, 18 6 12% with and 45 6 18%
without chronic GVHD, p , 0.01). Patients with leukemia
who received up to two ABs relapsed in 5% of the cases and
those with three ABs relapsed in 35 6 23%, p , 0.01.
Patients with grades II–IV overall acute GVHD also had a
lower risk of relapse with 5% incidence in 14 months of
median follow-up, compared with those with grade 0–I acute
GVHD who relapsed in 32 6 17%, p , 0.01 (standard-risk
leukemia, 14 6 13% with and 23 6 14% without grades
II–IV acute GVHD, p 5 0.78; high-risk leukemia, 3% with
and 67 6 14% without grades II–IV acute GVHD, p , 0.01)
(Fig. 6). In multivariate analysis, chronic GVHD and grades
II–IV overall acute GVHD are shown to be significant for
the relapse-free survival of patients with leukemia, both with
p , 0.01 (Table 5). Patients with multiple myeloma or lym-
Figure 3. Kaplan-Meier plots of proportional incidence of GVHD by
risk groups
(—), low-risk group; ( ), intermediate-risk group; (- - -), high-risk group.
Table 5. Results of multivariate analyses
Regression 
Variables coefficient Chi-square p
Acute GVHD after second 
T cell add-back
Unrelated/related 1.1738 7.159 0.007
Overall acute GVHD
Unrelated/related 0.6530 4.287 0.038
Risk groups 0.4059 3.918 0.048
Chronic GVHD
Unrelated/related 0.9104 8.504 0.004
Risk groups 0.4388 5.625 0.018
Acute GVHD 0.5887 3.135 0.077
GVHD mortality
Unrelated/related 1.3907 8.833 0.003
Number of add-backs 0.5624 3.4 0.065
Relapse-free survival
Chronic GVHD 0.9675 7.988 0.005
Acute GVHD 2.1085 5.998 0.014
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phoma do not reveal differences in the risk of relapse in this
study (data not shown).
Forty-five of 53 patients who developed chronic GVHD
were on continuous oral cyclosporine for at least the first 6
months of follow-up and 10 patients who did not develop
chronic GVHD received cyclosporine for a median duration
of 207 days (range 181–220 days). Twenty-nine patients
without chronic GVHD discontinued cyclosporine in a
median 106 days posttransplant (range 69–142 days), most
commonly within 4 weeks of the last T cell AB. In patients
with leukemia who did not develop chronic GVHD, there
was no difference in the relapse rate between 10 patients
who received cyclosporine at least for 6 months and 24
patients who discontinued cyclosporine early (25% vs. 34 6
19%, respectively, p 5 0.62).
DISCUSSION
The present study shows that the severity of GVHD can
be regulated, to a certain extent, by a 2-log depletion and
sequential AB of T cells with cyclosporine prophylaxis in
both related and unrelated allogeneic BMT. It results in a
significant reduction of mortality from acute GVHD despite
a high cumulative incidence, and is particularly effective for
the unrelated transplants with its low mortality of GVHD of
11.1 6 8.4% [52–54]. The reduction in mortality may be
attributed to the delay in the onset of acute GVHD in rela-
tion to transplantation, with five GVHD deaths occurring
within 2 months posttransplant; a low incidence of grades
III–IV acute GVHD after each AB; or a prompt response to
initial therapy, comparing favorably with the overall
responses of acute GVHD to the initial treatment in the
non–T cell–depleted BMT [55]. The overall incidence of
GVHD being equivalent to that of the non–T cell–depleted
BMT suggests that adding back T cells in the early phase of
transplant invariably induces GVHD and is concurrent with
other reports [4,56–57]. The high incidence during the early
phase of transplant may have been from a relatively high
number of remaining T cells in the graft after depletion and
inclusion of patients with HLA-mismatched and unrelated
transplants, since the threshold for acute GVHD after T cell
depletion in less than fully matched transplants is suggested
to be ,0.53105 CD31 T cells/kg [58–59]. Future studies
with more complete depletion of T cells should clarify the
relative role of graft T cells and AB T cells in this situation.
Graft failure is minimal in this study, with all three cases
from the unrelated recipients similar to the reported rate in
marrow transplants without T cell depletion [60]. We sus-
pect our 2-log depletion of T cells compared with the more
Figure 4. Kaplan-Meier plots of proportional incidence of chronic
GVHD by number of T cell add-backs and by antecedent grades
II–IV acute GVHD
(A) (—), two add-backs; ( ), one add-back; (- - -), three add-backs. (B) (—),
grades II–IV acute GVHD positive; ( ), no grades II–IV acute GVHD.
Figure 5. Kaplan-Meier plots of proportional incidence of GVHD-
related death
(A) (—), unrelated BMT; ( ), related BMT. (B) (—), HLA-mismatched
BMT; ( ), HLA-matched BMT.
A A
B B
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extensive depletion [8,61–62] and sequential infusions of T
cells in the immediate posttransplant period may have pre-
vented graft failure, since the intensity of immunosuppres-
sion of the ablative regimen is quite comparable to that in
the studies of non–T cell–depleted BMT. Previous studies
suggest that tolerant donor T cells prevent rejection medi-
ated by residual host effector cells, which recognize donor
major histocompatibility complex (MHC) class I antigens
through a veto mechanism, and nontolerant donor T cells
can prevent rejection caused by either MHC class I or II
disparity [63–67]. The present study suggests a small num-
ber of additional T cells in the range of 1–103105/kg with-
out subset selection may be sufficient to generate these
effects and is consistent with other studies [34,41]. Donor T
cells may induce and maintain a graft-vs.-host (GVH) effect
on host lymphocytes for the benefit of engraftment, but
recent findings in a murine transplant model suggest the ini-
tial process of engraftment may be adversely affected by T
cells and inflammatory cytokines causing GVHD [68–69].
Therefore, an increase in the incidence of GVHD by
sequential infusions of T cells may not be responsible for a
decrease in graft failure in the present study.
The current T cell titration aimed at inducing grade II
acute GVHD shows a distinct cell dose response, resulting in
a reduced incidence of greater than grade II acute GVHD in
patients able to receive a third AB and the highest incidence
of chronic GVHD in patients who had two ABs. These
observations may result from two factors of donor T cells
that determine the response—alloreactivity and number of T
cells—and are consistent with the findings of an association
of frequency and dose of cytotoxic and helper T lymphocytes
(CTLp; HTLp) with GVHD [70–72]. We reason that a cer-
tain percentage of patients show acute GVHD at a given
dose of T cells based on the HLA disparity and frequency of
CTLp, and patients who do not develop GVHD may have
received a dose of T cells with both the frequency of CTLp
and immunogenic potential of HLA disparity below a critical
level. The difference in the incidence between the second
and third ABs remains to be verified, yet we presume the
patients who do not develop GVHD after two ABs are not
sufficiently HLA disparate to develop GVHD under the cur-
rent circumstances. These observations suggest that patients
who do not show GVHD, regardless of T cell infusion, may
require additional measures such as interleukin (IL)-2. Alter-
natively, a decrease in the incidence of acute GVHD after the
third AB might be explained by a time-dependent process of
GVH reactivity equivalent to the GVHD of delayed T cell
infusion in murine models [40]. The mechanism of reduced
GVH reactivity in patients given delayed infusions of donor
T cells is unknown. Previous experimental data suggested an
active mechanism that suppressed recognition of host anti-
gens by the infused donor lymphocytes and the development
of GVHD [73]. Johnson et al. indicated the activation of both
host-reactive cytotoxic T lymphocytes and T-helper cells was
suppressed in chimeras given delayed infusions of donor cells
and suggested the activation of T-helper cells was preferen-
tially suppressed [40]. The role of selective suppression
remains uncertain since the relative importance of each T
cell subset in the GVL effect and GVHD is different among
various combinations of donor-recipient pairs in allogeneic
murine BMT of leukemia-bearing hosts [74–76]. Selective
CD4 T cell depletion in HLA-matched BMT did not pre-
vent GVHD, since three of four patients in the study died of
early grade IV acute GVHD [77]. Other possible time-
dependent mechanisms might be related to recovery of dam-
aged tissues by the conditioning regimen, associated with a
decrease in such inflammatory cytokines as IL-1 or tumor
necrosis factor (TNF) alpha released from host tissues that
enhance the presentation of host alloantigens to donor T
cells [78–80]. In this regard, Barrett et al. indicated that both
the time and the dose of T cell AB were critical, resulting in
no acute GVHD after a dose of 23106 CD31 cells/kg on
Day 30 and severe acute GVHD after 107 CD31 cells/kg in a
similar study of HLA-matched sibling BMT with T cell
Figure 6. Kaplan-Meier plots of relapse-free survival in patients
with leukemia
(A) (—), chronic GVHD positive; ( ), no chronic GVHD. (B) (—), two
add-backs; ( ), three add-backs. (C) (—), grades II–IV acute GVHD1;
( ), no grades II–IV acute GVHD.
A
B
C
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depletion and AB [57]. A follow-up study of adding back T
cells beginning more than 2 months after T cell–depleted
BMT may answer the question of whether decreased fre-
quency of acute GVHD after the third AB results from insuf-
ficient alloreactivity, insufficient T cell dose, or time-depen-
dent processes in our study.
The present study shows a beneficial effect on survival
associated with a high incidence of both chronic and acute
GVHD similar to the reports of non–T cell–depleted BMT
[5,11,81]. On the other hand, patients who were able to
receive three ABs because of no apparent acute GVHD
through two ABs do not show an increase in relapse-free
survival when compared with patients who ended up with
two ABs due to acute GVHD, indicating no apparent GVL
effect separate from GVHD. The findings suggest GVHD
is necessary in the current scheme for an increased survival.
Moreover, an independent GVL effect may not be expected
at the number of T cells equal to or higher than the present
study since the incidence of GVHD has already reached that
of non–T cell–depleted BMT. If GVL and GVHD are in
continuum and resolvable only by the number of T cells in
the graft, a more refined dose escalation scheme of smaller
increments for AB might induce an independent, measur-
able GVL effect at a certain T cell dose, but only in patients
who would be destined to have GVHD at a larger dose [30].
Concurrent with our observations, in a study with Cam-
path-1 antibody–T cell–depletion BMT from HLA-identi-
cal siblings and 4 weekly incremental ABs of T cells up to
107 cells/kg, Naparstek et al. reported a statistically signifi-
cant decrease in relapse of the patients with acute lym-
phoblastic leukemia who developed GVHD after donor T
lymphocytes compared with those without GVHD and indi-
cated the importance of chronic GVHD for leukemia-free
survival [56]. Of note, T cell infusion alone, without rele-
vance to chronic GVHD, was not found to be related to
leukemia-free survival in a multivariate analysis.
Posttransplant cyclosporine may also be considered
responsible for the lack of the GVL effect, since it is known
to mediate suppression of primary cytotoxic T lymphocyte
responses [82–84] and its use in experimental and clinical
transplants was associated with an increase in leukemia
relapse [85–86]. Furthermore, discontinuation of cyclo-
sporine has been shown to be associated with clinical
responses [87–88]. In our study, there was no difference in
leukemia-free survival between patients who were on pro-
longed cyclosporine despite no GVHD and patients who
discontinued cyclosporine about a month after the last T
cell AB, although the data should be interpreted with cau-
tion because of the inherent statistical bias of subset analysis.
A controlled study of GVHD prophylaxis with vs. without
cyclosporine may address the role of each cyclosporine and
sequential T cell AB in the GVL effect. However, we
believe it should be conducted only on the premise that the
high rate of GVHD in T cell–depleted BMT with T cell AB
can be adequately reduced without cyclosporine, since stud-
ies without posttransplant immunosuppression were largely
done by T cell–depleted BMT without T cell AB [4,88], the
majority of clinical studies with T cell AB were associated
with significant GVHD [4,56–57], and premature discontin-
uation of cyclosporine after T cell infusion was not infre-
quently associated with lethal GVHD [89].
Phenotypic and functional characterization of circulating
donor-derived T cells are necessary to see if persisting allore-
active T cells correlate with the long-term presence of anti-
leukemic activity similar to the allogeneic murine model with
delayed infusion of T cells [40]. Previous experimental stud-
ies with murine models indicated that Lyt21 (CD8) T cells
were critical for the induction of the GVL effect in MHC-
incompatible and MHC-compatible BMT, and the role of
L3T41 (CD4) T cells subset varied depending on donor-
host combinations or the type of leukemia or both
[22,75,76,90–91]. Although the GVL effects were well
demonstrated in both experimental and clinical studies, data
of unequivocal separation of the role of individual T cell sub-
sets in the GVL effect and GVHD are quite limited. Instead,
T cell subtypes and their relevant cytokines are known to be
highly interactive and dynamic, with CD41 T cells exacer-
bating CD8-mediated GVHD in a dose-dependent manner
[92]. Lethal GVHD responses can be mediated by either
CD41 T cells or CD4-dependent CD81 T cells, and GVHD
in a different combination of allogeneic murine models
involves either CD41 T cells alone or CD4-independent
CD81 T cells [93]. A randomized study of selective depletion
of CD81 T cells indicated that it reduced the incidence and
severity of acute GVHD without significant differences in
leukemia-free survival [94]. These data suggest infusion of
selective T cell subsets may have a role in inducing the GVL
effect in future trials.
In summary, the present study shows sequential infu-
sions of T cells in the T cell–depleted BMT increase the
incidence of acute and chronic GVHD. GVHD is associated
with a better relapse-free survival of patients with leukemia.
Important findings are: 1) the incidence of acute GVHD
after third AB is significantly lower than two earlier ABs; 2)
patients with leukemia who received all three ABs and did
not show GVHD had poorer leukemia-free survival, which
may not be related to cyclosporine; and, 3) even a 1-log
increase in T cells to 106/kg within 3 months of transplanta-
tion has the potential to induce significant acute GVHD.
The current study suggests the focus of future studies
should be on different times of AB rather than the number
of T cells, e.g., AB in more than 3 months posttransplant.
Patients who do not show GVHD regardless of T cell infu-
sion may require additional measures such as IL-2, as sug-
gested by Slavin et al. [88]. Further studies are needed to
confirm the current findings.
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